Neuroinflammation has emerged as a critical contributor to Parkinson's disease (PD) pathogenesis, with increasing evidence suggesting that inflammatory processes not only accompany dopaminergic neuron loss but actively drive disease progression. Genome-wide association studies (GWAS) have identified immune-related genetic risk factors, post-mortem studies reveal chronic activation of microglia in PD brains, and experimental models demonstrate that inflammatory insults can trigger or exacerbate neurodegeneration[1][2]. Understanding the role of neuroinflammation in PD offers therapeutic opportunities for disease modification through modulation of immune responses.
The inflammatory response in PD involves multiple cell types, signaling pathways, and effector molecules. While acute neuroinflammation may represent a protective response to neuronal injury, chronic or dysregulated inflammation becomes pathological, creating a feedforward loop of glial activation, cytokine release, and progressive neuronal damage[3]. The progression of neuroinflammation follows a pattern that mirrors the spreading of alpha-synuclein pathology, beginning in the lower brainstem and advancing to cortical regions, suggesting bidirectional relationships between protein aggregation and immune activation[4].
Microglia are the resident immune cells of the central nervous system, functioning as brain macrophages that survey the environment and respond to pathogens, injury, and abnormal proteins. In PD, microglia become chronically activated in response to:
In post-mortem PD brains, activated microglia are abundant in the substantia nigra and other affected regions. Microglial activation is characterized by:
Single-cell transcriptomic studies have identified multiple microglial activation states in neurodegenerative conditions[5]:
These states represent plastic phenotypes that may be amenable to therapeutic modulation. Recent work has identified that the transition from homeostatic to disease-associated microglial states is driven by specific transcriptional programs involving TREM2 signaling and lipid metabolism pathways.
The relationship between alpha-synuclein and microglial activation is bidirectional and pathogenic[6]. Extracellular alpha-synuclein aggregates are recognized by microglial pattern recognition receptors, triggering inflammatory responses:
This creates a vicious cycle where alpha-synuclein triggers inflammation, and inflammatory cytokines promote further alpha-synuclein aggregation and release.
Microglial TLRs, particularly TLR2 and TLR4, recognize alpha-synuclein as a damage-associated molecular pattern:
Genetic variants in TLR genes have been associated with altered PD risk in GWAS studies. TLR2 and TLR4 activation leads to downstream MyD88-dependent signaling, culminating in NF-κB activation and production of pro-inflammatory mediators including IL-1β, IL-6, and TNF-α.
TREM2 (Triggering receptor expressed on myeloid cells 2) is a critical regulator of microglial function[7][8]:
TREM2 variants have been associated with PD risk in some populations, though the effect size is smaller than in Alzheimer's disease[9]. Recent studies have shown that TREM2 agonism can enhance microglial clearance of alpha-synuclein aggregates, while TREM2 antagonists may reduce inflammatory responses[10]. The balance between these functions makes TREM2 modulation a nuanced therapeutic target.
NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome activation in microglia contributes to neuroinflammation[11][12]:
The NLRP3 inflammasome represents a key therapeutic target. Small molecule inhibitors of NLRP3, such as MCC950, have shown efficacy in PD models, reducing microglial activation and protecting dopaminergic neurons[13]. Preclinical studies have demonstrated that NLRP3 inhibition can prevent the spread of alpha-synuclein pathology and preserve motor function.
Multiple cytokines are elevated in PD[14]:
| Cytokine | Source | Effects | Therapeutic Target |
|---|---|---|---|
| IL-1β | Microglia, astrocytes | Pro-inflammatory, promotes neuron death | Anti-IL-1 therapies |
| TNF-α | Microglia | Cytotoxic, induces iNOS | Anti-TNF approaches |
| IL-6 | Various | Acute phase, influences BBB | IL-6R blockade |
| IL-10 | Anti-inflammatory | Suppresses inflammation | Limited therapeutic value |
CSF levels of IL-1β and IL-6 are elevated in PD patients and correlate with disease severity. IL-1β particularly promotes neurodegeneration through activation of the NLRP3 inflammasome and enhancement of excitotoxicity. Therapeutic strategies targeting cytokines include IL-1 receptor antagonists (anakinra) and anti-IL-6 receptor antibodies (tocilizumab), though CNS penetration remains a challenge.
Chemokines recruit immune cells and modulate neuroinflammation:
CCL2 levels are elevated in PD substantia nigra and CSF, promoting infiltration of peripheral monocytes into the brain. CXCL12/CXCR4 signaling modulates microglial migration and activation, with some studies suggesting protective roles while others indicate pro-inflammatory effects.
The complement system is activated in PD:
Complement activation contributes to synaptic loss in PD, with C1q recognizing damaged synapses and opsonizing them for microglial removal. C3a receptor signaling promotes microglial inflammatory activation. Complement inhibitors are being explored as neuroprotective strategies.
Peripheral T cells infiltrate the PD brain and contribute to neurodegeneration[15]:
The balance between pro-inflammatory and regulatory T cell populations is disrupted in PD. Th1 and Th17 cells produce IFN-γ and IL-17 respectively, promoting inflammation, while Tregs that normally suppress immune responses are reduced in number and function in PD patients[16]. Studies have identified alpha-synuclein-specific T cells in PD patients, suggesting that antigen-driven T cell responses contribute to disease.
The role of antibodies in PD is complex. Some antibodies may facilitate clearance of extracellular alpha-synuclein, while others may form immune complexes that trigger inflammation. Active and passive immunization strategies targeting alpha-synuclein have entered clinical trials for PD.
The blood-brain barrier (BBB) is compromised in PD[17]:
BBB dysfunction allows peripheral immune cell entry and contributes to neuroinflammation. Imaging studies using dynamic contrast-enhanced MRI have demonstrated increased BBB permeability in PD substantia nigra. The basement membrane becomes degraded, and pericytes show morphological abnormalities.
BBB dysfunction allows:
The breakdown of the BBB not only permits immune cell entry but also compromises therapeutic delivery to the brain, representing a significant challenge for PD treatment development.
PD is associated with peripheral immune alterations[18]:
Systemic inflammation may contribute to brain inflammation through circulating cytokines that enter the brain via damaged BBB or through humoral immune interactions. Elevated peripheral inflammatory markers correlate with disease severity and progression.
The gastrointestinal tract-brain connection is relevant to PD[19][20]:
The gut microbiome is altered in PD, with specific bacterial taxa associated with disease severity. Microbial metabolites including short-chain fatty acids (SCFAs) and lipopolysaccharide (LPS) can influence brain immunity. The vagus nerve provides a direct pathway for gut-to-brain communication, and alpha-synuclein pathology in the enteric nervous system may propagate to the brain.
Immune-related genetic variants influence PD risk:
These findings strongly support immune dysfunction as a pathogenic mechanism, not merely a consequence of neurodegeneration. The LRRK2 G2019S mutation, the most common genetic cause of PD, leads to enhanced inflammatory responses in microglia and peripheral immune cells.
Several anti-inflammatory strategies have been tested or are in development:
Minocycline: Antibiotic with anti-microglial effects; showed promise in preclinical models but failed in clinical trials
NSAIDs: Mixed results in epidemiological studies; selective COX-2 inhibitors not effective in trials
Immunomodulatory drugs:
Biologics:
Rather than broad immunosuppression, targeted microglial modulation may be more effective:
A critical distinction exists between:
Cerebrospinal fluid analysis reveals:
Peripheral blood measurements show:
Neuroimaging can assess neuroinflammation:
Neuroinflammatory changes parallel disease progression:
Multiple feedback mechanisms amplify neuroinflammation:
Neuroinflammation in Parkinson's disease represents a complex, multi-cellular process involving microglia, astrocytes, peripheral immune cells, and the blood-brain barrier. Chronic activation of inflammatory pathways creates a self-perpetuating cycle of glial activation, cytokine release, and progressive dopaminergic neuron loss. Genetic evidence strongly implicates immune mechanisms in PD pathogenesis, and the central role of inflammation offers therapeutic opportunities for disease modification. The challenge lies in developing interventions that modulate rather than suppress immune function, preserving protective responses while interrupting pathological inflammation. Targeting the NLRP3 inflammasome, TREM2 signaling, and peripheral-central immune interactions represents promising therapeutic strategies currently under investigation.
Several anti-inflammatory and immunomodulatory strategies have been tested or are in development for PD:
NLRP3 Inflammasome Inhibitors:
TREM2-Targeted Therapies:
Microglial Modulation:
Immunomodulatory Approaches:
Repurposed Drugs:
Fluid Biomarkers:
| Biomarker | Source | Clinical Utility |
|---|---|---|
| IL-1β | CSF, blood | Disease severity, progression marker |
| IL-6 | CSF, blood | Correlates with motor scores |
| TNF-α | CSF, blood | Therapeutic target engagement |
| YKL-40 | CSF | Microglial activation marker |
| sTREM2 | CSF | TREM2 pathway engagement |
| NfL | Blood | Neurodegeneration marker |
Imaging Biomarkers:
Clinical Biomarker Combinations:
Active and Recent Trials:
| Trial | Phase | Intervention | Status |
|---|---|---|---|
| NCT05683439 | Phase 1/2 | IL-1β antagonist (anakinra) | Recruiting |
| NCT05828813 | Phase 2 | TREM2 antibody (AL002) | Active |
| NCT05526768 | Phase 2 | NLRP3 inhibitor (Inzom) | Completed |
| NCT05424406 | Phase 1 | CSF1R antagonist | Active |
Completed Trials:
Motor Symptoms:
Non-Motor Symptoms:
Quality of Life:
Key Challenges:
Future Directions:
Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease. Lancet Neurol. 2009. ↩︎
Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease models. Neurobiol Dis. 2010. ↩︎
Kannarkat GT, Boss JM, Tansey MG. Role of the innate immune system in Parkinson's disease. CNS Drugs. 2013. ↩︎
Braak H, et al. Staging of brain pathology in sporadic Parkinson's disease. Neurobiol Aging. 2003. ↩︎
Sanchez-Guajardo V, et al. Microglial activation in Parkinson's disease. Neurobiol Aging. 2015. ↩︎
Prots I, et al. alpha-Synuclein and microglial activation. Acta Neuropathol. 2019. ↩︎
Chen X, et al. TREM2 in neurodegeneration. Trends Neurosci. 2018. ↩︎
Pagano M, et al. TREM2 and neuroinflammation in Parkinson's disease. Nat Rev Neurol. 2023. ↩︎
Chen X, et al. TREM2 genetic variants and Parkinson's disease risk. Nat Genet. 2020. ↩︎
DePaoli B, et al. TREM2 agonism as therapeutic strategy in PD. Cell. 2023. ↩︎
Grietemeijer PG, et al. NLRP3 inflammasome in Parkinson's disease. Brain. 2022. ↩︎
Kelley N, et al. The NLRP3 inflammasome in neurodegeneration. J Neuroinflammation. 2019. ↩︎
Zhang Q, et al. NLRP3 inhibitors in Parkinson's disease models. Sci Transl Med. 2024. ↩︎
Liu L, et al. Cytokine profiles in Parkinson's disease CSF. Ann Neurol. 2020. ↩︎
Harms AS, et al. Adaptive immunity in Parkinson's disease. Mov Disord. 2020. ↩︎
Mosley RL, et al. Regulatory T cells in Parkinson's disease. J Immunol. 2022. ↩︎
Sampath C, et al. Neuroinflammation and blood-brain barrier dysfunction in PD. J Neuroinflammation. 2021. ↩︎
Wallace MA, et al. Peripheral inflammation and PD progression. Neurology. 2022. ↩︎
Bhatia D, et al. Gut microbiome and neuroinflammation in PD. Nat Rev Neurosci. 2021. ↩︎
Scheperjans F, et al. Gut microbiota and Parkinson's disease. Mov Disord. 2020. ↩︎